Mr. Breton has become a prominent voice over the past decade for improving access to gene therapies as a means to create a better quality of life for individuals struggling with incurable and chronic diseases.
Calimmune is focused on developing gene therapies that enhance the body’s own defenses to defeat disease. Under Mr. Breton’s leadership, Calimmune’s lead program for treatment of HIV positive patients for whom traditional treatments are not effective has advanced to Phase I/II clinical trials. Advances in this program will establish Calimmune as a leader in ex-vivo gene therapy (gene modification of the patient’s own cells performed outside the body for reinfusion). Calimmune is building on this platform with next-generation gene therapy programs directed toward new outpatient treatments for hematologic diseases.
Calimmune Inc. is a clinical-stage, international biotechnology company focused on developing novel gene therapies that have the potential to improve and protect the lives of patients by enhancing their immune system. Calimmune’s lead therapeutic candidate, now in Phase I/II clinical studies, is being evaluated as a one-time treatment to prevent HIV progression to AIDS. Calimmune’s development pipeline includes additional outpatient treatments for hematologic diseases. The company’s clinical and laboratory operations are based in Pasadena, California and Sydney, Australia. Calimmune’s corporate office is located in Tucson, Arizona.